SNP-based arrays complement classic cytogenetics in the detection of chromosomal aberrations in Wilms' tumor

Cancer Genetics

Volumn 205, Issue 3, 2012, Pages 80-93

  Zin, Reena ^a,b   Pham, Kym ^c   Ashleigh, Murch ^a,f   Ravine, David ^d   Waring, Paul ^e   Charles, Adrian ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITI KEBANGSAAN MALAYSIA MEDICAL CENTER   (Malaysia)

^c PATHWEST LABORATORY MEDICINE   (Australia)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^e UNIVERSITY OF MELBOURNE   (Australia)

^f KING EDWARD MEMORIAL HOSPITAL   (Australia)

Author keywords

Cytogenetics; SNP array; Wilms' tumors

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CHROMOSOME INVERSION; CHROMOSOME LOSS; CHROMOSOME TRANSLOCATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISOMY; DNA MICROARRAY; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; KARYOTYPING; NEPHROBLASTOMA; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

CHROMOSOME ABERRATIONS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN; CHROMOSOMES, HUMAN, PAIR 11; CYTOGENETIC ANALYSIS; FEMALE; GENE DOSAGE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; KARYOTYPE; MALE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; UNIPARENTAL DISOMY; WILMS TUMOR;

EID: 84860252268     PISSN: 22107762     EISSN: 22107770     Source Type: Journal    
DOI: 10.1016/j.cancergen.2011.12.003     Document Type: Article

References (44)

1. Breslow N., Olshan A., Beckwith J.B., et al. Epidemiology of Wilms tumor. Medical Pediatric Oncology 1993, 21:172-181.
2. Kaneko Y., Egues M.C., Rowley J.D. Interstitial deletion of short arm of chromosome 11 limited to Wilms' tumor cells in a patient without aniridia. Cancer Res 1981, 41:4577-4578.
3. Pelletier J., Bruening W., Kashtan C.E., et al. Germline mutations in the Wilms' tumor suppressor gene are associated with abnormal urogenital development in Denys-Drash syndrome. Cell 1991, 67:437-447.
4. Reeve A.E., Sih S.A., Raizis A.M., et al. Loss of allelic heterozygosity at a second locus on chromosome 11 in sporadic Wilms' tumor cells. Mol Cell Biol 1989, 9:1799-1803.
5. Grundy R.G., Pritchard J., Scambler P., et al. Loss of heterozygosity for the short arm of chromosome 7 in sporadic Wilms tumour. Oncogene 1998, 17:395-400.
6. Powlesland R.M., Charles A.K., Malik K.T., et al. Loss of heterozygosity at 7p in Wilms' tumour development. Br J Cancer 2000, 82:323-329.
7. Ogawa O., Eccles M.R., Szeto J., et al. Relaxation of insulin-like growth factor II gene imprinting implicated in Wilms' tumour. Nature 1993, 362:749-751.
8. Koesters R., Ridder R., Kopp-Schneider A., et al. Mutational activation of the beta-catenin proto-oncogene is a common event in the development of Wilms' tumors. Cancer Res 1999, 59:3880-3882.
9. Rivera M.N., Kim W.J., Wells J., et al. An X chromosome gene, WTX, is commonly inactivated in Wilms tumor. Science 2007, 315:642-645.
10. Ruteshouser E.C., Robinson S.M., Huff V. Wilms tumor genetics: mutations in WT1, WTX, and CTNNB1 account for only about one-third of tumors. Genes Chromosomes Cancer 2008, 47:461-470.
11. Wegert J., Wittmann S., Leuschner I., et al. WTX inactivation is a frequent, but late event in Wilms tumors without apparent clinical impact. Genes Chromosomes Cancer 2009, 48:1102-1111.
12. Maiti S., Alam R., Amos C.I., et al. Frequent association of beta-catenin and WT1 mutations in Wilms tumors. Cancer Res 2000, 60:6288-6292.
13. Perotti D., Gamba B., Sardella M., et al. Functional inactivation of the WTX gene is not a frequent event in Wilms' tumors. Oncogene 2008, 27:4625-4632.
14. Getman M.E., Houseal T.W., Miller G.A., et al. Comparative genomic hybridization and its application to Wilms' tumorigenesis. Cytogenet Cell Genet 1998, 82:284-290.
15. Hing S., Lu Y.J., Summersgill B., et al. Gain of 1q is associated with adverse outcome in favorable histology Wilms' tumors. Am J Pathol 2001, 158:393-398.
16. Steenman M., Redeker B., de Meulemeester M., et al. Comparative genomic hybridization analysis of Wilms tumors. Cytogenet Cell Genet 1997, 77:296-303.
17. Cowell J.K., Wang Y.D., Head K., et al. Identification and characterisation of constitutional chromosome abnormalities using arrays of bacterial artificial chromosomes. Br J Cancer 2004, 90:860-865.
18. Goldstein M., Rennert H., Bar-Shira A., et al. Combined cytogenetic and array-based comparative genomic hybridization analyses of Wilms tumors: amplification and overexpression of the multidrug resistance associated protein 1 gene (MRP1) in a metachronous tumor. Cancer Genet Cytogenet 2003, 141:120-127.
19. Natrajan R., Williams R.D., Hing S.N., et al. Array CGH profiling of favourable histology Wilms tumours reveals novel gains and losses associated with relapse. J Pathol 2006, 210:49-58.
20. Rassekh S.R., Chan S., Harvard C., et al. Screening for submicroscopic chromosomal rearrangements in Wilms tumor using whole-genome microarrays. Cancer Genet Cytogenet 2008, 182:84-94.
21. Haruta M., Arai Y., Sugawara W., et al. Duplication of paternal IGF2 or loss of maternal IGF2 imprinting occurs in half of Wilms tumors with various structural WT1 abnormalities. Genes Chromosomes Cancer 2008, 47:712-727.
22. Ohshima J., Haruta M., Arai Y., et al. Two candidate tumor suppressor genes, MEOX2 and SOSTDC1, identified in a 7p21 homozygous deletion region in a Wilms tumor. Genes Chromosomes Cancer 2009, 48:1037-1050.
23. Yuan E., Li C.M., Yamashiro D.J., et al. Genomic profiling maps loss of heterozygosity and defines the timing and stage dependence of epigenetic and genetic events in Wilms' tumors. Mol Cancer Res 2005, 3:493-502.
24. Benetkiewicz M., de Stahl T.D., Gordor A., et al. Identification of limited regions of genetic aberrations in patients affected with Wilms' tumor using a tiling-path chromosome 22 array. Int J Cancer 2006, 119:571-578.
25. Natrajan R., Little S.E., Sodha N., et al. Analysis by array CGH of genomic changes associated with the progression or relapse of Wilms' tumour. J Pathol 2007, 211:52-59.
26. Schaub R., Burger A., Bausch D., et al. Array comparative genomic hybridization reveals unbalanced gain of the MYCN region in Wilms tumors. Cancer Genet Cytogenet 2007, 172:61-65.
27. Major M.B., Camp N.D., Berndt J.D., et al. Wilms tumor suppressor WTX negatively regulates WNT/beta-catenin signaling. Science 2007, 316:1043-1046.
28. Huang J., Wei W., Zhang J., et al. Whole genome DNA copy number changes identified by high density oligonucleotide arrays. Hum Genomics 2004, 1:287-299.
29. Perlman E.J. Pediatric renal tumors: practical updates for the pathologist. Pediatr Dev Pathol 2005, 320:320-338.
30. Pandis N., Heim S., Bardi G., et al. Improved technique for short-term culture and cytogenetic analysis of human breast cancer. Genes Chromosomes Cancer 1992, 5:14-20.
31. ISCN 1995: an international system for human cytogenetic nomenclature. Recommendations of the International Standing Committee on Human Cytogenetic Nomenclature, Memphis, Tennessee, October 9-13, 1994 1995, Karger, Basel; Farmington, CT. F. Mitelman (Ed.).
32. ISCN 2009: an international system for human cytogenetic nomenclature 2009, Karger, Basel. L.G. Shaffer, M.L. Slovak, L.J. Campbell (Eds.).
33. MdZin R., Murch A., Charles A. Cytogenetic findings in Wilms' tumour: a single institute study. Pathology (Phila) 2011, 42:643-649.
34. Mdzin R.R., Phillips M.B., Edwards C., et al. Perilobar nephrogenic rests and chromosome 22. Pediatr Dev Pathol 2011, [Epub ahead of print.].
35. Han M., Rivera M.N., Batten J.M., et al. Wilms' tumor with an apparently balanced translocation t(X;18) resulting in deletion of the WTX gene. Genes Chromosomes Cancer 2007, 46:909-913.
36. Bown N., Cotterill S.J., Roberts P., et al. Cytogenetic abnormalities and clinical outcome in Wilms tumor: a study by the U.K. cancer cytogenetics group and the U.K. Children's Cancer Study Group. Med Pediatr Oncol 2002, 38:11-21.
37. Hoglund M., Gisselsson D., Hansen G.B., et al. Wilms tumors develop through two distinct karyotypic pathways. Cancer Genet Cytogenet 2004, 150:9-15.
38. Kullendorff C.M., Soller M., Wiebe T., et al. Cytogenetic findings and clinical course in a consecutive series of Wilms tumors. Cancer Genet Cytogenet 2003, 140:82-87.
39. Gow K.W., Murphy J.J. Cytogenetic and histologic findings in Wilms' tumor. J Pediatr Surg 2002, 37:823-827.
40. Klamt B., Schulze M., Thate C., et al. Allele loss in Wilms tumors of chromosome arms 11q, 16q, and 22q correlate with clinicopathological parameters. Genes Chromosomes Cancer 1998, 22:287-294.
41. Pei J., Feder M.M., Al-Saleem T., et al. Combined classical cytogenetics and microarray-based genomic copy number analysis reveal frequent 3;5 rearrangements in clear cell renal cell carcinoma. Genes Chromosomes Cancer 2010, 49:610-619.
42. Tuna M., Knuutila S., Mills G.B. Uniparental disomy in cancer. Trends Mol Med 2009, 15:120-128.
43. Grundy P.E., Telzerow P.E., Breslow N., et al. Loss of heterozygosity for chromosomes 16q and 1p in Wilms' tumors predicts an adverse outcome. Cancer Res 1994, 54:2331-2333.
44. Henry I., Bonaiti-Pellie C., Chehensse V., et al. Uniparental paternal disomy in a genetic cancer-predisposing syndrome. Nature 1991, 351:665-667.